Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldoxorubicin in HIV-associated Kaposi's Sarcoma
NCT02029430Phase 2Completed
- Sponsor
- ImmunityBio, Inc.
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aldoxorubicin in Kaposi's sarcoma (KS), sponsored by ImmunityBio, Inc.. Started Apr 2014; status: completed.
02
Drugs
aldoxorubicin
03
Conditions
Kaposi's sarcoma (KS)
Beyond the preview
Go deeper on NCT02029430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02029430.